Zeria Pharmaceutical
- View a machine-translated version of the Japanese article.
- Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
- Consider adding a topic to this template: there are already 1,074 articles in the main category, and specifying
|topic=
will aid in categorization. - Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
- You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is
Content in this edit is translated from the existing Japanese Wikipedia article at [[:ja:ゼリア新薬工業]]; see its history for attribution.
- You may also add the template
{{Translated|ja|ゼリア新薬工業}}
to the talk page. - For more guidance, see Wikipedia:Translation.
Zeria Shinyaku Kōgyō KK (ゼリア新薬工業株式会社, Zeria Shinyaku Kōgyō Kabushiki-gaisha, Zeria Pharmaceutical Co., Ltd.) is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku[1] executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho (Zeria Pharmaceutical and Cosmetics Laboratory). In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance[2] as of March 2023.
Products
Zeria holds a leading position within the gastroenterology field in Japan.[3]
In 2019, the pain reliever cream EPATEC (ketoprofen) firstly developed by Nissan Chemical Corporation was revocated authorization of Ministry of Health, Labour and Welfare around the contraindications for women in the third trimester of pregnancy.[4][5][6]
References
External links
- Zeria Pharmaceutical